Wegovy and Mounjaro have been conditionally reimbursed in France since June 2026. BFMTV reports that specialist obesity centres are now facing heavy demand, with waits exceeding a year at some institutions.
For people seeking obesity care, reimbursement is therefore only one part of access. The report places the two developments alongside each other: medicines may be covered under conditions, while specialist appointments and follow-up can still take a long time to obtain.
That makes care capacity the central issue raised by this development. A reimbursed medicine is not automatically a prompt clinical pathway when assessment and follow-up depend on specialist services with long queues. The reported waits are a practical barrier alongside the cost question, even though the material does not establish that reimbursement itself caused the increase in demand.
BFMTV does not specify the reimbursement criteria or prescription process, and its report does not give national waiting-list figures. The waits of more than a year concern some institutions, rather than every specialist obesity centre in France. The source also provides no basis for judging the effectiveness, risks or suitability of either medicine for an individual patient.
Sources
- BFMTV Actualités · Source date: 2026-11-14
Independent editorial content. WUA is not affiliated with any political party. 2026-11-14